Top

Published in:

01-08-2011 | Erratum

Erratum to: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer

Authors: Andrea H Bild, Joel S Parker, Adam M Gustafson, Chaitanya R Acharya, Katherine A Hoadley, Carey Anders, P Kelly Marcom, Lisa A Carey, Anil Potti, Joseph R Nevins, Charles M Perou

Published in: Breast Cancer Research | Issue 4/2011

Excerpt

In our previous publication [1], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [2, 3]). It has recently been determined that the chemotherapy-response signatures in [2] are not reproducible, causing retraction of that article [3]. As such, the results presented in Figure 4 of our original paper [1] are no longer valid. …

Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res. 2009, 11: R55-10.1186/bcr2344.CrossRefPubMedPubMedCentral

Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006, 12: 1294-1300. 10.1038/nm1491.CrossRefPubMed

Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR: Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2011, 17: 135-10.1038/nm0111-135.CrossRefPubMed

Title: Erratum to: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
Authors: Andrea H Bild
Joel S Parker
Adam M Gustafson
Chaitanya R Acharya
Katherine A Hoadley
Carey Anders
P Kelly Marcom
Lisa A Carey
Anil Potti
Joseph R Nevins
Charles M Perou
Publication date: 01-08-2011
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 4/2011
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2909

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2011

Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression

Vitamin D and breast cancer: interpreting current evidence

Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response

Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10

NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

Keynote webinar | Spotlight on antibody–drug conjugates in cancer